Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
28.16
+0.27 (+0.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Royalty Pharma Plc Cl A
< Previous
1
2
Next >
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
Today 8:15 EDT
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
April 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
February 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2023 Results
February 15, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
January 30, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Dividend Increase
January 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
November 27, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Royalty Pharma Reports Third Quarter 2023 Results
November 08, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
October 19, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2023 Dividend
October 16, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
October 11, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 21, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
August 24, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
August 24, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
Royalty Pharma Reports Second Quarter 2023 Results
August 08, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
July 18, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Third Quarter 2023 Dividend
July 17, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports First Quarter 2023 Results
May 09, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
May 03, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2023 Dividend
April 17, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
April 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
March 27, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
March 23, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
March 23, 2023
From
PureTech Health plc
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.